CN1775784A - Purification method of ceftazidime - Google Patents
Purification method of ceftazidime Download PDFInfo
- Publication number
- CN1775784A CN1775784A CN 200410090879 CN200410090879A CN1775784A CN 1775784 A CN1775784 A CN 1775784A CN 200410090879 CN200410090879 CN 200410090879 CN 200410090879 A CN200410090879 A CN 200410090879A CN 1775784 A CN1775784 A CN 1775784A
- Authority
- CN
- China
- Prior art keywords
- ceftazidime
- ceftazime
- polymer
- pentahydrate
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000000746 purification Methods 0.000 title claims description 14
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 title abstract description 55
- 229960000484 ceftazidime Drugs 0.000 title abstract description 52
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960003547 ceftazidime pentahydrate Drugs 0.000 claims abstract description 37
- 239000013078 crystal Substances 0.000 claims abstract description 32
- 239000000706 filtrate Substances 0.000 claims abstract description 29
- 239000012535 impurity Substances 0.000 claims abstract description 24
- 239000003513 alkali Substances 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 claims abstract 2
- 239000007864 aqueous solution Substances 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 238000000247 postprecipitation Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 26
- 238000002425 crystallisation Methods 0.000 abstract description 5
- 230000008025 crystallization Effects 0.000 abstract description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 description 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- 239000005457 ice water Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- 150000004686 pentahydrates Chemical class 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- JLZLIGALAZXURA-ZYMGEXDGSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxylatopropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydron;dihydrochloride Chemical compound Cl.Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 JLZLIGALAZXURA-ZYMGEXDGSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- -1 amorphous ceftazime Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及头孢他啶的纯化方法,更具体地说,涉及由不纯的、含聚合物杂质的头孢他啶通过结晶制备高品质的头孢他啶五水合物的方法。The present invention relates to a method for purifying ceftazime, in particular to a method for preparing high-quality ceftazime pentahydrate from impure ceftazime containing polymer impurities through crystallization.
背景技术Background technique
头孢他啶五水合物是临床上应用极广泛的头孢菌素,其结构式如下所示:Ceftazidime pentahydrate is a cephalosporin widely used clinically, and its structural formula is as follows:
为了确保人体用药安全,国家药典规定,对于头孢他啶抗生素,要求头孢他啶五水合物的含量不低于95%,聚合物的含量不高于0.3%,其色泽不高于6号色。头孢他啶抗生素在存放过程中,特别是遭受高温(>50℃)的情况下,往往发生降解和聚合反应,生成头孢他啶二聚物、三聚物和多聚物等等聚合物,从而导致药物活性成分含量降低,色泽加强,聚合物杂质含量升高。另外,过期的头孢他啶抗生素,由于存放时间过长,也常常是药物活性成分含量降低,颜色变深,聚合物含量升高。还有,在某些情况下,由于生产工艺控制不当,所得到的头孢他啶五水合物,头孢他啶二聚物、三聚物和多聚物等等聚合物含量特别高。而聚合物含量高时,易使人体产生过敏反应。所以对于这类聚合物杂质含量高的头孢他啶五水合物或头孢他啶药物制剂,有必要进一步进行纯化,得到高品质的、纯度高的头孢他啶五水合物晶体。In order to ensure the safety of human medicine, the National Pharmacopoeia stipulates that for ceftazidime antibiotics, the content of ceftazidime pentahydrate is not less than 95%, the content of polymer is not more than 0.3%, and its color is not higher than No. 6 color. During storage, ceftazidime antibiotics tend to degrade and polymerize, especially when subjected to high temperature (>50°C), to form polymers such as ceftazidime dimers, trimers and polymers, which lead to the formation of active ingredients of the drug. The content is reduced, the color is strengthened, and the content of polymer impurities is increased. In addition, due to the long storage time of expired ceftazidime antibiotics, the content of active ingredients of the drug is often reduced, the color becomes darker, and the polymer content increases. Also, in some cases, due to improper control of the production process, the obtained ceftazime pentahydrate, ceftazime dimer, trimer and multipolymer, etc. have a particularly high content of polymers. When the polymer content is high, it is easy to cause allergic reactions in the human body. Therefore, for ceftazidime pentahydrate or ceftazime pharmaceutical preparations with high polymer impurity content, it is necessary to further purify to obtain high-quality, high-purity ceftazidime pentahydrate crystals.
GB2063871披露了头孢他啶五水合物晶体的制备方法,该方法是调节头孢他啶酸盐或碱盐水溶液的pH为3.3~4.0,使头孢他啶五水合物晶体结晶析出。上述聚合物杂质含量较高的头孢他啶五水合物或头孢他啶药物制剂,例如,聚合物杂质含量高于4%时,按照GB2063871的方法结晶纯化,聚合物杂质往往伴随着头孢他啶五水合物晶体一起析出,所以,所得到的头孢他啶五水合物晶体中聚合物杂质的含量依旧很高。GB2063871 discloses a method for preparing ceftazidime pentahydrate crystals. The method is to adjust the pH of ceftazidime salt or alkali salt solution to 3.3-4.0, so that ceftazidime pentahydrate crystals are precipitated. For ceftazidime pentahydrate or ceftazidime pharmaceutical preparations with higher polymer impurity content, for example, when the polymer impurity content is higher than 4%, crystallization and purification according to the method of GB2063871, the polymer impurity is often precipitated together with the ceftazidime pentahydrate crystal, Therefore, the content of polymer impurities in the obtained crystals of ceftazidime pentahydrate is still high.
GB2157682公开了一种头孢他啶的回收方法,该方法是采用非功能大孔网状树脂,与pH为2.0~5.5头孢他啶水溶液接触,从而吸收头孢他啶,再进行洗脱,分离出头孢他啶或其盐或其水合物。按照这种方法,最终产物可能为头孢他啶或其盐或其水合物,杂质聚合物含量降低,产品色泽变浅,但该方法需要使用非功能大孔网状树脂,再进行洗脱、分离,工序多,操作繁琐,成本高。GB2157682 discloses a method for recovering ceftazidime. The method is to use a non-functional macroporous network resin to contact with an aqueous solution of ceftazidime with a pH of 2.0 to 5.5, thereby absorbing ceftazidime, and then eluting to separate ceftazidime or its salt or its hydration. thing. According to this method, the final product may be ceftazidime or its salt or its hydrate, the content of impurity polymers is reduced, and the color of the product becomes lighter, but this method requires the use of non-functional macroporous network resin, followed by elution and separation. Many, complicated operation and high cost.
US4659813公开了一种头孢他啶五水合物晶体的制备方法,该方法是,在约5~15℃的温度下,pH为约5.5~约6.5的头孢他啶水溶液,用酸调节其pH为约4.0~约4.7,并在结晶过程中通过控制酸的加入,使pH保持在约4.0~约4.7,从而析出头孢他啶五水合物晶体。虽然这种方法对提高产品纯度,降低聚合物含量有一定帮助,但对于聚合物含量很高、色泽很差的头孢他啶制剂,按照此方法,仍得不到高品质的头孢他啶五水合物晶体。同时,此方法先将物料溶于pH较高的体系中,致使头孢他啶有所降解,这样回收率降低。US4659813 discloses a method for preparing ceftazidime pentahydrate crystals, the method is, at a temperature of about 5-15 ° C, the pH of ceftazime aqueous solution is about 5.5-about 6.5, and the pH is adjusted to about 4.0-about 4.7 with acid , and by controlling the addition of acid during the crystallization process, the pH is maintained at about 4.0 to about 4.7, thereby separating out ceftazidime pentahydrate crystals. Although this method is helpful to improve product purity and reduce polymer content, for the ceftazidime preparation with very high polymer content and poor color, according to this method, high-quality ceftazidime pentahydrate crystals still cannot be obtained. Simultaneously, this method first dissolves material in the higher system of pH, causes ceftazidime to degrade to some extent, and the rate of recovery reduces like this.
发明内容Contents of the invention
因此,本发明的目的在于,针对杂质聚合物含量高的头孢他啶提供一种简便的、能有效除去聚合物杂质的头孢他啶纯化方法,也即制备高品质头孢他啶五水合物晶体的方法。Therefore, the object of the present invention is to provide a simple method for purifying ceftazime that can effectively remove polymer impurities for ceftazime with high content of impurity polymers, that is, a method for preparing high-quality ceftazime pentahydrate crystals.
本发明提供一种含聚合物杂质的头孢他啶的纯化方法,该方法包括:The invention provides a method for purifying ceftazidime containing polymer impurities, the method comprising:
将含聚合物杂质的头孢他啶加入水中,任选地加入酸使其溶解,得到头孢他啶水溶液;然后用碱或酸调节头孢他啶水溶液的pH为1.5~2.5,有沉淀析出;过滤除去沉淀,所得到的滤液继续用碱调节pH为3.5~4.8,控制温度在0~40℃,头孢他啶五水合物晶体结晶析出。Add ceftazidime containing polymer impurities into water, optionally add an acid to dissolve it, and obtain an aqueous solution of ceftazidime; then use alkali or acid to adjust the pH of the aqueous solution of ceftazidime to 1.5 to 2.5, and precipitates are precipitated; filter to remove the precipitates, and the obtained filtrate Continue to use alkali to adjust the pH to 3.5-4.8, control the temperature at 0-40° C., and crystallize ceftazidime pentahydrate.
不纯的、聚合物含量高的头孢他啶五水合物、头孢他啶盐酸盐或头孢他啶氢溴酸盐以及过期的或从市面上回收来的头孢他啶制剂,均可以采用本发明的方法,进行精制,得到纯的头孢他啶五水合物。对于不纯的、含聚合物的头孢他啶五水合物,将其分散于水中,加酸使其溶解,得到头孢他啶水溶液;不纯的、含聚合物的头孢他啶盐酸盐或头孢他啶氢溴酸盐,可直接溶于水中,得到头孢他啶水溶液;不纯的、含聚合物的头孢他啶制剂,例如头孢他啶含碳酸钠或头孢他啶含精氨酸,可直接溶于水中,得到头孢他啶水溶液。在本发明的方法中,这样得到的头孢他啶水溶液,头孢他啶含量一般为5wt.%~60wt.%,优选10wt.%~40wt.%。Ceftazime pentahydrate, ceftazime hydrochloride or ceftazime hydrobromide with high polymer content and expired or recovered ceftazime preparations from the market can be refined by the method of the present invention to obtain pure ceftazidime pentahydrate. For impure, polymer-containing ceftazime pentahydrate, disperse it in water, add acid to dissolve it, and obtain ceftazime aqueous solution; for impure, polymer-containing ceftazime hydrochloride or ceftazime hydrobromide, you can Dissolve directly in water to obtain ceftazidime aqueous solution; impure, polymer-containing ceftazidime preparations, such as ceftazidime containing sodium carbonate or ceftazidime containing arginine, can be directly dissolved in water to obtain ceftazidime aqueous solution. In the method of the present invention, the ceftazidime aqueous solution obtained in this way generally has a ceftazime content of 5wt.%-60wt.%, preferably 10wt.%-40wt.%.
所述的聚合物杂质为头孢他啶在制备和存放过程中所生成的头孢他啶二聚物、三聚物和多聚物等等聚合物的混合物,当这些聚合物杂质在头孢他啶中的含量高于1wt.%时,尤其适于采用本发明的方法进行纯化。Described polymer impurity is the mixture of polymers such as ceftazime dimer, trimer and multipolymer generated by ceftazime in the preparation and storage process, when the content of these polymer impurities in ceftazime is higher than 1wt. %, it is especially suitable for purification by the method of the present invention.
用于本发明方法中的酸可以为无机酸或有机酸,其中所述的无机酸包括盐酸、磷酸或硫酸,优选盐酸;所述的有机酸包括甲酸或乙酸。所述的酸的加入方式,优选采用在搅拌下滴加的方式。The acid used in the method of the present invention can be inorganic acid or organic acid, wherein said inorganic acid includes hydrochloric acid, phosphoric acid or sulfuric acid, preferably hydrochloric acid; said organic acid includes formic acid or acetic acid. The adding method of the acid is preferably dropwise under stirring.
用于本发明方法中的碱包括无机碱或有机碱,其中所述的无机碱包括氢氧化钠溶液、氢氧化钾溶液、乙酸钠、异辛酸钠或氨水等;所述的有机碱包括三乙胺或正丁胺等。所述的碱的加入方式,优选采用在搅拌下滴加的方式。The alkali used in the method of the present invention includes inorganic alkali or organic alkali, wherein said inorganic alkali includes sodium hydroxide solution, potassium hydroxide solution, sodium acetate, sodium isooctanoate or ammoniacal liquor etc.; Described organic alkali includes triethyl Amine or n-butylamine, etc. The adding method of the base is preferably dropwise under stirring.
在本发明提供的纯化方法中,在由含聚合物杂质的头孢他啶配制头孢他啶水溶液时,通常在0~30℃温度下进行。然后用碱或酸调节头孢他啶水溶液的pH为1.5~2.5,此时聚合物杂质基本上全部析出,同时伴随有少量的头孢他啶(约为溶液中头孢他啶总量的0.5%~2%)一起析出,通过过滤,从而除去了聚合物杂质。过滤后所得到的滤液用碱调节pH为3.5~4.8,优选4.0~4.6,此时头孢他啶五水合物晶体开始析出,析晶温度控制在0~40℃,优选5~30℃,并在此温度下搅拌或者静置养晶1~10小时。而后,经过滤、溶剂洗涤、干燥,得到头孢他啶五水合物晶体。In the purification method provided by the present invention, when the ceftazidime aqueous solution is prepared from ceftazidime containing polymer impurities, it is usually carried out at a temperature of 0-30°C. Then adjust the pH of ceftazidime aqueous solution with alkali or acid to be 1.5~2.5, now the polymer impurity basically all separates out, simultaneously with a small amount of ceftazidime (about 0.5%~2% of the ceftazime total amount in the solution) to separate out together, by Filtration to remove polymer impurities. The obtained filtrate after filtration is adjusted to pH 3.5~4.8 with alkali, preferably 4.0~4.6, at this moment ceftazidime pentahydrate crystal begins to separate out, crystallization temperature is controlled at 0~40 ℃, preferably 5~30 ℃, and at this temperature Stir or stand still to grow crystals for 1 to 10 hours. Then, after filtration, solvent washing and drying, ceftazidime pentahydrate crystals were obtained.
在本发明所提供的头孢他啶纯化方法中,为了得到色泽好的头孢他啶五水合物晶体,优选在纯化过程中加入活性碳进行脱色,活性碳的用量为含聚合物杂质的头孢他啶的2%~30%(重量)。In the method for purifying ceftazime provided by the present invention, in order to obtain ceftazime pentahydrate crystals with good color and luster, it is preferable to add activated carbon to decolorize during the purification process, and the consumption of activated carbon is 2% to 30% of that of ceftazime containing polymer impurities (weight).
本发明的优点在于:本发明的方法尤其适用于聚合物杂质含量高的头孢他啶五水合物、无定形头孢他啶、头孢他啶盐或头孢他啶药物制剂的纯化,纯化后所得到的头孢他啶五水合物晶体纯度高,聚合物含量低,例如,低于0.2%,达到药典规定要求。该方法操作简便,成本低,安全性好,收率高。The advantages of the present invention are: the method of the present invention is especially suitable for the purification of ceftazime pentahydrate, amorphous ceftazime, ceftazidime salt or ceftazidime pharmaceutical preparations with high polymer impurity content, and the obtained ceftazime pentahydrate crystals after purification have high purity, The polymer content is low, for example, less than 0.2%, meeting the Pharmacopoeia requirements. The method is simple to operate, low in cost, good in safety and high in yield.
具体实施方式Detailed ways
在本发明中,根据《中国药典》(2000版,第171页至172页,化学工业出版社)规定的测定方法,采用高效液相色谱法测定头孢他啶的含量,照柱色谱法测定头孢他啶聚合物的含量,以下所指含量均按照《中国药典》(2000版)所述按干燥品计算。In the present invention, according to the assay method stipulated in "Chinese Pharmacopoeia" (2000 edition, page 171 to page 172, Chemical Industry Press), adopt high performance liquid chromatography to measure the content of ceftazidime, according to column chromatography to measure ceftazime polymer The content of the following content is calculated according to the dry product according to "Chinese Pharmacopoeia" (2000 edition).
下面提供的实施例是用来具体地说明本发明的实施方案,这些实施例不限制本发明的范围。The following examples are provided to specifically illustrate the embodiments of the present invention, and these examples do not limit the scope of the present invention.
实施例1Example 1
不合格的头孢他啶五水合物,由高效液相色谱法测定头孢他啶的含量为90.1wt.%,由照柱色谱法测定聚合物的含量为8.5wt.%。For unqualified ceftazime pentahydrate, the content of ceftazime determined by high performance liquid chromatography is 90.1wt.%, and the content of polymer determined by illuminating column chromatography is 8.5wt.%.
将上述不合格的头孢他啶五水合物20.0g悬浮于100ml水中,用冰水浴冷却至0~5℃,边搅拌边滴加36wt.%浓盐酸至物料溶清,得到头孢他啶水溶液。在搅拌条件下,向头孢他啶水溶液中滴加2N的NaOH溶液,调pH至2.5,析出类白色的沉淀,滤去沉淀(沉淀湿重1.99g,HPLC检测含头孢他啶0.25g),得到滤液。然后,所得到的滤液再用冰水浴升温至5~10℃,搅拌下滴加2N的NaOH溶液,使pH为4.0,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃,搅拌养晶8小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水合物16.0g。摩尔收率为87.9%,含量98.5wt%,聚合物0.08wt.%,干燥失重14.0wt.%。Suspend 20.0 g of the unqualified ceftazidime pentahydrate in 100 ml of water, cool to 0-5° C. in an ice-water bath, and add 36 wt.% concentrated hydrochloric acid dropwise while stirring until the material dissolves to obtain an aqueous solution of ceftazidime. Under stirring condition, in the ceftazidime aqueous solution, dropwise add 2N NaOH solution, adjust pH to 2.5, separate out off-white precipitate, filter off precipitate (precipitate wet weight 1.99g, HPLC detection contains ceftazidime 0.25g), obtain filtrate. Then, the resulting filtrate was heated up to 5-10°C in an ice-water bath, and 2N NaOH solution was added dropwise with stirring to make the pH 4.0, ceftazidime pentahydrate crystals were precipitated, and the temperature was adjusted to 0-5°C in an ice-water bath. , stirring and growing the crystal for 8 hours. Thereafter, it was suction filtered, washed with 30 ml of water and then with 50 ml of acetone, drained, and vacuum-dried to obtain 16.0 g of ceftazidime pentahydrate. The molar yield is 87.9%, the content is 98.5wt%, the polymer is 0.08wt.%, and the drying weight loss is 14.0wt.%.
实施例2Example 2
将实施例1的不合格的头孢他啶五水合物20.0g悬浮于100ml水中,用冰水浴冷却至0~5℃,边搅拌边滴加99wt.%乙酸至物料溶清,得到澄清的头孢他啶水溶液。然后,向所得到的头孢他啶水溶液中加入0.5g活性碳,搅拌脱色30分钟,而后过滤除去活性碳,得到滤液。所得到的滤液继续用冰水浴使温度处于0~5℃,在搅拌条件下,滴加22wt.%氨水,调pH至2.0,析出类白色的沉淀,滤去沉淀,得到滤液。然后,所得到的滤液再用水浴升温至20~25℃,搅拌下滴加22wt.%氨水,使pH为4.2,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃静止养晶6小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水合物15.0g。摩尔收率83.2%,含量98.9wt.%,聚合物0.07wt.%,干燥失重13.9wt.%。20.0 g of the unqualified ceftazime pentahydrate of Example 1 was suspended in 100 ml of water, cooled to 0-5° C. with an ice-water bath, and 99 wt.% acetic acid was added dropwise while stirring until the material was dissolved to obtain a clarified aqueous solution of ceftazime. Then, 0.5 g of activated carbon was added to the obtained aqueous solution of ceftazidime, stirred and decolorized for 30 minutes, and then filtered to remove the activated carbon to obtain a filtrate. The resulting filtrate was kept in an ice-water bath to keep the temperature at 0-5°C. Under stirring, 22 wt.% ammonia water was added dropwise to adjust the pH to 2.0. An off-white precipitate was precipitated, and the precipitate was filtered off to obtain the filtrate. Then, the resulting filtrate was heated to 20-25°C in a water bath, and 22wt.% ammonia water was added dropwise under stirring, so that the pH was 4.2, and ceftazidime pentahydrate crystals were precipitated, and then the temperature was adjusted to 0-5°C in an ice-water bath. Crystal growth for 6 hours. Thereafter, it was suction filtered, washed with 30 ml of water and then 50 ml of acetone, drained, and vacuum-dried to obtain 15.0 g of ceftazidime pentahydrate. The molar yield is 83.2%, the content is 98.9wt.%, the polymer is 0.07wt.%, and the drying weight loss is 13.9wt.%.
实施例3Example 3
将实施例1的不合格的头孢他啶五水合物20.0g悬浮于30ml水中,用冰水浴冷却至0~5℃,边搅拌边滴加36wt.%盐酸至物料溶清,得到澄清的头孢他啶水溶液。然后,向所得到的头孢他啶水溶液中加入0.5g活性碳,搅拌脱色30分钟,而后过滤除去活性碳,得到滤液。所得到的滤液继续用冰水浴使温度处于0~5℃,在搅拌条件下,滴加22wt.%氨水,调pH至2.0,析出类白色的沉淀,滤去沉淀,得到滤液。然后,所得到的滤液再用水浴升温至20~25℃,搅拌下滴加22wt.%氨水,使pH为3.8,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃养晶4小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水合物15.5g。摩尔收率86.0%,含量98.8wt.%,聚合物0.08wt.%,干燥失重14.1wt.%。20.0 g of the unqualified ceftazime pentahydrate of Example 1 was suspended in 30 ml of water, cooled to 0-5° C. with an ice-water bath, and 36 wt.% hydrochloric acid was added dropwise while stirring until the material was dissolved to obtain a clarified aqueous solution of ceftazime. Then, 0.5 g of activated carbon was added to the obtained aqueous solution of ceftazidime, stirred and decolorized for 30 minutes, and then filtered to remove the activated carbon to obtain a filtrate. The resulting filtrate was kept in an ice-water bath to keep the temperature at 0-5°C. Under stirring, 22 wt.% ammonia water was added dropwise to adjust the pH to 2.0. An off-white precipitate was precipitated, and the precipitate was filtered off to obtain the filtrate. Then, the resulting filtrate is heated to 20-25°C in a water bath, and 22wt.% ammonia water is added dropwise under stirring, so that the pH is 3.8, and ceftazidime pentahydrate crystals are precipitated, and then the temperature is adjusted to 0-5°C in an ice-water bath. Crystal 4 hours. Thereafter, it was suction filtered, washed with 30 ml of water and then 50 ml of acetone, drained, and dried in vacuo to obtain 15.5 g of ceftazidime pentahydrate. The molar yield is 86.0%, the content is 98.8wt.%, the polymer is 0.08wt.%, and the weight loss on drying is 14.1wt.%.
实施例4Example 4
在室温23℃,将实施例1的不合格的头孢他啶五水合物20g悬浮于160ml水中,边搅拌边滴加36wt.%盐酸至物料溶清,得到澄清的头孢他啶水溶液。向所得到的头孢他啶水溶液中加入1g活性碳,搅拌脱色15分钟,而后过滤除去活性碳,得到滤液。所得到的滤液在搅拌下滴加三乙胺,调pH至1.8,析出类白色的沉淀,滤去沉淀,得到滤液。然后,所得到的滤液在搅拌下滴加三乙胺,使pH为3.9,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃,搅拌养晶1小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水合物11.2g。摩尔收率61.7%,含量98.5wt.%,聚合物0.1wt.%,干燥失重14.1wt.%。At a room temperature of 23° C., 20 g of unqualified ceftazime pentahydrate of Example 1 was suspended in 160 ml of water, and 36 wt.% hydrochloric acid was added dropwise while stirring until the material was dissolved to obtain a clear aqueous solution of ceftazidime. Add 1 g of activated carbon to the obtained ceftazidime aqueous solution, stir and decolorize for 15 minutes, then filter to remove the activated carbon to obtain a filtrate. The obtained filtrate was added dropwise with triethylamine under stirring to adjust the pH to 1.8, and an off-white precipitate was precipitated, which was filtered off to obtain a filtrate. Then, triethylamine was added dropwise to the obtained filtrate under stirring, so that the pH was 3.9, ceftazime pentahydrate crystals were precipitated, and then the temperature was adjusted to 0-5° C. in an ice-water bath, and the crystals were grown with stirring for 1 hour. Thereafter, it was suction filtered, washed with 30 ml of water and then with 50 ml of acetone, drained, and vacuum-dried to obtain 11.2 g of ceftazidime pentahydrate. The molar yield is 61.7%, the content is 98.5wt.%, the polymer is 0.1wt.%, and the loss on drying is 14.1wt.%.
实施例5Example 5
将实施例1的不合格的头孢他啶五水合物20g悬浮于40ml水中,用冰水浴冷却至0~5℃,边搅拌边滴加36wt.%盐酸至物料溶清,得到澄清的头孢他啶水溶液。然后,向所得到的头孢他啶水溶液中加入3g活性碳,搅拌脱色50分钟,而后过滤除去活性碳,得到滤液。所得到的滤液用水浴使温度处于10~15℃,在搅拌条件下,滴加1.5N乙酸钠,调pH至2.0,析出类白色的沉淀,滤去沉淀,得到滤液。然后,所得到的滤液再用水浴调温至10~15℃,搅拌下滴加1.5N乙酸钠,使pH为4.0,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃静止养晶3小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水物16.1g。摩尔收率89.1%,含量98.0wt.%,聚合物0.12wt.%,干燥失重14.2wt.%。Suspend 20 g of the unqualified ceftazime pentahydrate of Example 1 in 40 ml of water, cool to 0-5° C. in an ice-water bath, and add 36 wt.% hydrochloric acid dropwise while stirring until the material dissolves to obtain a clarified aqueous solution of ceftazime. Then, 3 g of activated carbon was added to the obtained aqueous solution of ceftazidime, stirred and decolorized for 50 minutes, and then filtered to remove the activated carbon to obtain a filtrate. The obtained filtrate was kept at 10-15°C in a water bath, and 1.5N sodium acetate was added dropwise with stirring to adjust the pH to 2.0. An off-white precipitate was precipitated, and the precipitate was filtered off to obtain a filtrate. Then, adjust the temperature of the obtained filtrate to 10-15°C with a water bath, add 1.5N sodium acetate dropwise under stirring to make the pH 4.0, ceftazidime pentahydrate crystals are precipitated, and then adjust the temperature to 0-5°C with an ice-water bath Static crystal growth for 3 hours. Thereafter, it was suction filtered, washed with 30 ml of water and then with 50 ml of acetone, drained, and vacuum-dried to obtain 16.1 g of ceftazidime pentahydrate. The molar yield is 89.1%, the content is 98.0wt.%, the polymer is 0.12wt.%, and the weight loss on drying is 14.2wt.%.
实施例6Example 6
不合格的头孢他啶盐酸盐,由高效液相色谱法测定头孢他啶的含量为93.1wt.%,由照柱色谱法测定聚合物的含量为5.5wt.%。For unqualified ceftazime hydrochloride, the content of ceftazime determined by high performance liquid chromatography is 93.1wt.%, and the content of polymer determined by illuminating column chromatography is 5.5wt.%.
将上述不合格的头孢他啶盐酸盐20g加至100ml水中,用冰水浴冷却至0~5℃,得到头孢他啶水溶液。在搅拌条件下,向所得到的头孢他啶水溶液中滴加8N异辛酸钠,调pH至2.5,析出类白色沉淀,滤去沉淀,得到滤液。然后,所得到的滤液再用冰水浴保持至0~5℃,搅拌下滴加8N异辛酸钠,使pH为4.4,头孢他啶五水合物晶体析出,静止养晶5小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水物15.0g。摩尔收率80.6%,含量99.2wt.%,聚合物0.1wt.%,干燥失重14.0wt.%。Add 20 g of the unqualified ceftazidime hydrochloride to 100 ml of water, and cool to 0-5° C. in an ice-water bath to obtain an aqueous solution of ceftazidime. Under stirring conditions, 8N sodium isooctanoate was added dropwise to the obtained ceftazidime aqueous solution to adjust the pH to 2.5, and an off-white precipitate was precipitated, which was filtered off to obtain a filtrate. Then, the obtained filtrate was kept at 0-5°C in an ice-water bath, and 8N sodium isooctanoate was added dropwise with stirring to make the pH 4.4, ceftazidime pentahydrate crystals were precipitated, and the crystals were grown statically for 5 hours. Then suction filter, first wash with 30ml of water, then with 50ml of acetone, drain, and vacuum-dry to obtain 15.0g of ceftazidime pentahydrate. The molar yield is 80.6%, the content is 99.2wt.%, the polymer is 0.1wt.%, and the weight loss on drying is 14.0wt.%.
实施例7Example 7
不合格的头孢他制剂,由高效液相色谱法测定头孢他啶的含量为81.5%,由照柱色谱法测定聚合物的含量为5.5wt.%,碳酸钠10wt.%(按美国药典XXIV版第351页测定方法)。Unqualified ceftazidime preparations, the content of ceftazidime measured by high performance liquid chromatography is 81.5%, and the content of polymer measured by illuminating column chromatography is 5.5wt.%, sodium carbonate 10wt.% (according to USP XXIV edition 351 page measurement method).
将上述不合格的头孢他制剂20g加至80ml中,溶解,用冰水浴冷却至0~5℃,边搅拌边滴加6N盐酸调pH至1,得到头孢他啶水溶液。在搅拌条件下,向所得到的头孢他啶水溶液中滴加6NNaOH调pH至2.4,析出类白色沉淀,滤去沉淀,得到滤液。然后,所得到的滤液再用水浴升温至20~25℃,搅拌下滴加6NNaOH调pH至3.7,头孢他啶五水合物晶体逐渐析出,再用冰水浴将温度调节至0~5℃静止养晶5小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水物13.2g。摩尔收率81.0%,含量99.1wt.%,聚合物0.06wt.%,干燥失重13.9wt.%。Add 20 g of the unqualified ceftazidime preparation to 80 ml, dissolve, cool to 0-5° C. in an ice-water bath, and add 6N hydrochloric acid dropwise while stirring to adjust the pH to 1 to obtain an aqueous solution of ceftazidime. Under stirring conditions, 6N NaOH was added dropwise to the obtained aqueous solution of ceftazidime to adjust the pH to 2.4, an off-white precipitate was precipitated, and the precipitate was filtered off to obtain a filtrate. Then, the resulting filtrate was heated to 20-25°C in a water bath, and 6N NaOH was added dropwise under stirring to adjust the pH to 3.7, and ceftazidime pentahydrate crystals were gradually precipitated, and then the temperature was adjusted to 0-5°C in an ice-water bath to grow crystals statically. Hour. Then suction filter, first wash with 30ml of water, then with 50ml of acetone, drain, and vacuum-dry to obtain 13.2g of ceftazidime pentahydrate. The molar yield is 81.0%, the content is 99.1wt.%, the polymer is 0.06wt.%, and the weight loss on drying is 13.9wt.%.
实施例8Example 8
将实施例1的不合格的头孢他啶五水合物20g悬浮于120ml水中,边搅拌边滴加99wt.%乙酸至物料溶清,得到澄清的头孢他啶水溶液。然后,在30~35℃温度,在搅拌条件下,向所得到的溶液中滴加22wt.%氨水,调pH至1.6,析出类白色的沉淀,滤去沉淀,得到滤液。所得到的滤液搅拌下滴加22wt.%氨水,使pH为4.7,头孢他啶五水合物晶体析出,再用冰水浴将温度调节至0~5℃静止养晶6小时。而后抽滤,先用30ml水、然后用50ml丙酮洗涤,抽干,真空干燥,得头孢他啶五水合物14.2g。摩尔收率78.8%,含量98.4wt.%,聚合物0.09wt.%,干燥失重13.7wt.%。20 g of unqualified ceftazime pentahydrate of Example 1 was suspended in 120 ml of water, and 99 wt.% acetic acid was added dropwise while stirring until the material was dissolved to obtain a clarified aqueous solution of ceftazime. Then, 22wt.% ammonia water was added dropwise to the obtained solution under stirring condition at a temperature of 30-35° C. to adjust the pH to 1.6, and an off-white precipitate was precipitated, which was filtered off to obtain a filtrate. 22 wt.% ammonia water was added dropwise to the obtained filtrate with stirring to make the pH to 4.7, ceftazidime pentahydrate crystals were precipitated, and then the temperature was adjusted to 0-5° C. in an ice-water bath for 6 hours of static growth. Thereafter, it was filtered by suction, washed with 30 ml of water and then with 50 ml of acetone, drained, and dried in vacuo to obtain 14.2 g of ceftazidime pentahydrate. The molar yield is 78.8%, the content is 98.4wt.%, the polymer is 0.09wt.%, and the loss on drying is 13.7wt.%.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410090879XA CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410090879XA CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1775784A true CN1775784A (en) | 2006-05-24 |
CN1328281C CN1328281C (en) | 2007-07-25 |
Family
ID=36765521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410090879XA Expired - Lifetime CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1328281C (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103044457A (en) * | 2012-10-22 | 2013-04-17 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
CN103467496A (en) * | 2013-09-29 | 2013-12-25 | 广州白云山制药股份有限公司广州白云山化学制药厂 | Preparing method of 7-((thiazolyl hydroxyl imino group) acetamido)-3-methyl cephalosporanic acid and another purpose |
CN103864819A (en) * | 2014-03-31 | 2014-06-18 | 悦康药业集团有限公司 | Ceftazidime compound and pharmaceutical composition thereof |
CN109824698A (en) * | 2019-01-23 | 2019-05-31 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of cefotaxime |
CN110396104A (en) * | 2018-07-26 | 2019-11-01 | 赛法洛抗生素有限公司 | The New Indication of Tesitin Ceftazidime in the Treatment of Gynecological Infections |
CN110857308A (en) * | 2018-08-24 | 2020-03-03 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
CN111196818A (en) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
CN112345669A (en) * | 2020-11-17 | 2021-02-09 | 海南卫康制药(潜山)有限公司 | Method for measuring ceftazidime polymer for injection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
US4659813A (en) * | 1984-11-08 | 1987-04-21 | Eli Lilly And Company | Crystallization process for ceftazidime derivative |
-
2004
- 2004-11-16 CN CNB200410090879XA patent/CN1328281C/en not_active Expired - Lifetime
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103044457A (en) * | 2012-10-22 | 2013-04-17 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
CN103044457B (en) * | 2012-10-22 | 2014-07-02 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
CN103467496A (en) * | 2013-09-29 | 2013-12-25 | 广州白云山制药股份有限公司广州白云山化学制药厂 | Preparing method of 7-((thiazolyl hydroxyl imino group) acetamido)-3-methyl cephalosporanic acid and another purpose |
CN103864819A (en) * | 2014-03-31 | 2014-06-18 | 悦康药业集团有限公司 | Ceftazidime compound and pharmaceutical composition thereof |
CN110396104A (en) * | 2018-07-26 | 2019-11-01 | 赛法洛抗生素有限公司 | The New Indication of Tesitin Ceftazidime in the Treatment of Gynecological Infections |
CN110857308A (en) * | 2018-08-24 | 2020-03-03 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
CN110857308B (en) * | 2018-08-24 | 2021-02-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
CN111196818A (en) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
CN109824698A (en) * | 2019-01-23 | 2019-05-31 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of cefotaxime |
CN112345669A (en) * | 2020-11-17 | 2021-02-09 | 海南卫康制药(潜山)有限公司 | Method for measuring ceftazidime polymer for injection |
Also Published As
Publication number | Publication date |
---|---|
CN1328281C (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5898067A (en) | Crystallization of proteins | |
CN101613359B (en) | Method for synthesizing cefuroxime sodium | |
US9090631B2 (en) | Process for purifying cefotiam hydrochloride | |
CN1775784A (en) | Purification method of ceftazidime | |
WO2013010296A1 (en) | Novel method for preparing cefmenoxime hydrochloride compound | |
CN1209364C (en) | Amine salt of cefathiamiding, its preparing method and application | |
CN105683170A (en) | Method of refining valsartan comprising more than 10% d-isomers | |
US20070213313A1 (en) | Direct process for the production of an amino acid dihydrochloride | |
KR19980701852A (en) | How to recover cephalexin | |
CN114409677B (en) | Preparation method of high-purity cefotaxime acid | |
CA2427199C (en) | Process for the production of ceftiofur sodium salt | |
CN112279817B (en) | Preparation method of high-purity pramipexole dihydrochloride | |
CN105440054A (en) | Process for preparing high-purity cefathiamidine | |
CN112142740B (en) | Process for the preparation of imipenem | |
CN110857308B (en) | Preparation method of ceftazidime for injection | |
CN1830982A (en) | Method for recovering cefaclor | |
CN1257270C (en) | method for improving lipase activity stability | |
US20190062265A1 (en) | Process for purifying long chain amino acids | |
CN1063431C (en) | Method for preparing phenyl alanine without water crystal | |
CN1876628A (en) | Method for preparing levocysteine and dextral cysteine using chemical resolution method | |
CN1256319C (en) | Process for synthesis of L-beta-asparagine | |
US20070060560A1 (en) | Process for producing the dihydrochloride of amino acids | |
CN108069970B (en) | Preparation method of pralatrexate | |
CN1295234C (en) | Cefuroxime axetil diastereoisomer separating method | |
CN118324674A (en) | Method for removing tyrosine impurities in carbocisteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20070725 |
|
CX01 | Expiry of patent term |